DRUG SAFETY ASSESSMENT IN CLINICAL TRIALS: CONCEPTS AND ISSUES

被引:1
|
作者
Nautiyal, Naveen [1 ]
Rastogi, Rajul [1 ]
Gamperl, Hans-Joachim [1 ]
机构
[1] Fresenius Kabi Oncol Ltd, Global Vigilance, Gurgaon 122001, Haryana, India
关键词
Pharmacovigilance; Adverse Event; Adverse Drug Reactions; Clinical Trial; Drug Safety;
D O I
10.13040/IJPSR.0975-8232.6(10).4159-67
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ensuring patient safety during and after clinical trials is the sole priority of the drug-development process. In both clinical trials and clinical practice, each patient must be treated according to his or her illness and needs. For this purpose, monitoring of patient safety at all levels of drug-development is given utmost importance. Such monitoring is a dynamic process having motive of protecting trial volunteers and patients from preventable harm during and after clinical trials respectively. For this purpose, knowledge of the basics of drug safety at all levels is essential especially for the healthcare professionals. Many literatures have been published on drug safety and clinical trials but a systemic document focusing strictly on all the dimensions is lacking. In this article, we have discussed upon all aspects of drug safety in clinical trials including the basics of drug safety, patient suitability for safety in trials, regulatory aspects of drug safety, causality, risk assessment and post marketing safety of the drug products.
引用
收藏
页码:4159 / 4167
页数:9
相关论文
共 50 条
  • [41] Harnessing the Power of Proteomics to Assess Drug Safety and Guide Clinical Trials
    Lam, Maggie P. Y.
    Ge, Ying
    [J]. CIRCULATION, 2018, 137 (10) : 1011 - 1014
  • [42] Drug related adverse event assessment in neonates in clinical trials and clinical care
    Yalcin, Nadir
    van den Anker, John
    Samiee-Zafarghandy, Samira
    Allegaert, Karel
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (09) : 803 - 816
  • [43] Testing drug response in the presence of genetic information: sampling issues for clinical trials
    Cardon, LR
    Idury, RM
    Harris, TJR
    Witte, JS
    Elston, RC
    [J]. PHARMACOGENETICS, 2000, 10 (06): : 503 - 510
  • [44] ASSESSMENT OF PERIODONTAL TISSUES DAMPING CHARACTERISTICS - CURRENT CONCEPTS AND CLINICAL-TRIALS
    VANSTEENBERGHE, D
    ROSENBERG, D
    NAERT, IE
    VANDENBOSSCHE, L
    NYS, M
    [J]. JOURNAL OF PERIODONTOLOGY, 1995, 66 (03) : 165 - 170
  • [45] Responding to drug safety issues
    Waller, PC
    Lee, EH
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 1999, 8 (07) : 535 - 552
  • [46] Noninvasive assessment of left ventricular remodeling: Concepts, techniques, and implications for clinical trials
    Anand, IS
    Florea, VG
    Solomon, SD
    Konstam, MA
    Udelson, JE
    [J]. JOURNAL OF CARDIAC FAILURE, 2002, 8 (06) : S452 - S464
  • [49] Statistical issues in clinical trials
    Black, D.
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S15 - S15
  • [50] Issues in the design of clinical trials
    Feldman, Martha A.
    [J]. Medical Device and Diagnostic Industry, 1993, 15 (11): : 96 - 102